Amyloid Beta and Cognition in Parkinson Disease

Completed

Conditions studied: Parkinson Disease, Neurological Disorders

In brief

The investigators propose to study persons with Parkinson Disease (PD) with detailed clinical, cognitive and imaging at the time of study entry and repeat these assessments 2 years later. The study looks at how changes in activity of the neurotransmitter acetylcholine relates to changes in cognitive function and to see if there is presence or build up of amyloid protein.

Key facts

Study ID

NCT01754168

Run by

University of Michigan

People needed

44

Starts

2013-02-01

Expected to finish

2018-02-01

Last updated by the study team

2018-03-08

Who can join

Age: 65 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• PD diagnosis according to the UK PD Society of Brain Bank research Center criteria PD subjects at risk for dementia Age 50 and above, male or female Absence of dementia confirmed by clinical and detailed neurological assessment -

You may not qualify if…

• Subjects with contra-indications to MR imaging Evidence of large vessel stroke or mass on on MRI Use of cholinergic or neuroleptic drugs at baseline Evidence of atypical parkinsonism on neurological exam Subjects limited by participation in research procedures involving ionizing radiation Pregnancy(test within 48 hours of each PET session) or breastfeeding

Where it is running

• University of Michigan Health System — Ann Arbor, Michigan, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.